IMPEDIMED LIMITED — Board/Management Information 2011

Jul 11, 2011

==> picture [73 x 81] intentionally omitted <==

Tuesday 12 July 2011

Australian Securities Exchange Announcement

APPOINTMENT OF DR. CHERRELL HIRST AO AS DEPUTY CHAIR

Brisbane, Australia – The Board of ImpediMed Limited has with great pleasure today announced the appointment of Dr. Cherrell Hirst as Deputy Chair. Dr. Hirst is a Non‐executive Director and has served on the Board of Directors of ImpediMed since 24 March 2005.

Cherrell Hirst is a medical doctor and was a leading practitioner in the area of breast cancer diagnosis. Cherrell serves on the Remuneration Committee, the Audit Committee and Nomination Committee. Cherrell is also Deputy Chair and Chief Executive Officer of Queensland BioCapital Funds and sits on other commercial Boards including MediBank Private.

ImpediMed Chairman Mel Bridges said, “In addition to Dr. Hirst’s distinguished clinical career in the detection and diagnosis of breast cancer, Dr. Hirst has extensive and highly respected achievements in both commercial and not‐for‐profit organizations. Cherrell’s substantial business experience and her work with breast cancer patients give her a unique insight and empathy into the need for preemptive care for all women who are at risk for secondary lymphoedema after breast cancer treatment.”

In recognition of her exceptional contributions to the nation, Dr. Hirst has received multiple awards including Officer of the Order of Australia, General Division, 1998; Centenary Medal, 2001; Queenslander of the Year, 1995 and multiple Honorary Doctorates from Australian universities.

ENDS For further information contact:

Greg Brown Mel Bridges ImpediMed CEO ImpediMed Chair T: 61‐7‐3860‐3700 Mobile/Cell: +61408281127

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement has been prepared for publication in Australia and New Zealand and may not be distributed or released in the United States. This announcement does not constitute promotion for the use of BIS devices in the United States or in any other jurisdiction in which such device clearance has not been obtained.

Page 1 of 1